Merck Phase 3 Trial of Sac-TMT Meets Overall Survival Endpoint
Merck said its Phase 3 trial of sac-TMT in advanced gastroesophageal cancer met the overall survival endpoint.
Merck said its Phase 3 trial of sac-TMT in advanced gastroesophageal cancer met the overall survival endpoint.